LDN-025

LDN-025 is an orally administered peptide mimic developed by Ladon Therapeutics using its proprietary A3SMO® (Artificial Amino Acid-based Small Molecule) platform. It is designed as a first-in-class therapeutic that targets A3SMO and has been specifically described as an inhibitor of epithelial sodium channel (ENaC) expression. By reducing the overexpression and overactivation of ENaC, LDN-025 decreases harmful sodium uptake, making it a candidate for the treatment of cystic fibrosis across all CFTR genotypes. Additionally, the A3SMO technology allows for the creation of stable, orally bioavailable molecules intended to address unmet needs in autoimmune diseases, fibrosis, and obesity by providing anti-inflammatory and anti-fibrotic effects.